Poseida Therapeutics Inc
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies an… Read more
Poseida Therapeutics Inc (PSTX) - Total Liabilities
Latest total liabilities as of September 2024: $206.37 Million USD
Based on the latest financial reports, Poseida Therapeutics Inc (PSTX) has total liabilities worth $206.37 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Poseida Therapeutics Inc - Total Liabilities Trend (2017–2023)
This chart illustrates how Poseida Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Poseida Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Poseida Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gabriel India Limited
NSE:GABRIEL
|
India | ₹9.82 Billion |
|
Thanh Thanh Cong Tay Ninh JSC
VN:SBT
|
Vietnam | ₫23.66 Trillion |
|
Wuxi ETEK Microelectronics Co Ltd
SHG:688601
|
China | CN¥141.44 Million |
|
Voltamp Transformers Limited
NSE:VOLTAMP
|
India | ₹2.56 Billion |
|
Hatsun Agro Product Limited
NSE:HATSUN
|
India | ₹26.00 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | ₹69.50 Billion |
|
BIEM.L .FDLKK Garment Co Ltd
SHE:002832
|
China | CN¥1.89 Billion |
Liability Composition Analysis (2017–2023)
This chart breaks down Poseida Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Poseida Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Poseida Therapeutics Inc (2017–2023)
The table below shows the annual total liabilities of Poseida Therapeutics Inc from 2017 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $170.18 Million | +3.62% |
| 2022-12-31 | $164.24 Million | +45.22% |
| 2021-12-31 | $113.10 Million | +3.27% |
| 2020-12-31 | $109.52 Million | -63.06% |
| 2019-12-31 | $296.51 Million | +143.36% |
| 2018-12-31 | $121.84 Million | +106.51% |
| 2017-12-31 | $59.00 Million | -- |